Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

References

• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3(6), 415–428 (2002).
   PubMed Web of Science ®Google Scholar
• Rice JC, Allis CD. Code of silence. Nature414(6861), 258–261 (2001).
   PubMed Web of Science ®Google Scholar
• Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood94(2), 417–428 (1999).
   PubMed Web of Science ®Google Scholar
• Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br. J. Haematol.118(3), 714–727 (2002).
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.349(21), 2042–2054 (2003).
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell128(4), 683–692 (2007).
   PubMed Web of Science ®Google Scholar
• Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer6(11), 846–856 (2006).
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst.92(15), 1210–1216 (2000).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol.2(3), 150–157 (2005).
   PubMedGoogle Scholar
• Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood98(9), 2865–2868 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol.125(5), 1045–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Peart MJ, Tainton KM, Ruefli AA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res.63(15), 4460–4471 (2003).
   PubMed Web of Science ®Google Scholar
• Burgess AJ, Pavey S, Warrener R et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol.60(4), 828–837 (2001).
   PubMed Web of Science ®Google Scholar
• Peart MJ, Smyth GK, van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA102(10), 3697–3702 (2005).
   PubMed Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol.23(17), 3971–3993 (2005).
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J. Cell Biochem.96(2), 293–304 (2005).
   PubMed Web of Science ®Google Scholar
• Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med.134, 573–586 (2001).
   PubMed Web of Science ®Google Scholar
• Uchida T, Knoshita T, Nagai H et al. Hypermethylation of p15ink4b gene in myelodysplastic syndromes. Blood90, 1403–1409 (1997).
   PubMed Web of Science ®Google Scholar
• Quesnel B, Guillerm G, Verecque R et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood91, 2985–2990 (1998).
   PubMed Web of Science ®Google Scholar
• Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res.61(8), 3225–3229 (2001).
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science293(5532), 1074–1080 (2001).
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res.13(8), 2318–2322 (2007).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M et al. Update of the NCI multiinstitutional Phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. American Society of Clinical Oncology Annual Meeting Abstracts25, 8027 (2007).
   Google Scholar
• Lerner A, Demierre MF, Whittaker S et al. Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: interim report of a Phase II multicenter study. American Society of Hematology Annual Meeting Abstracts (2006) (Abstract 2468).
   Google Scholar
• Prince HM, George D, Patnaik A et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma. American Society of Clinical Oncology Annual Meeting Proceedings Part I25(Suppl. 18), 35002 (2007).
   Google Scholar
• Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood109(1), 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol.24(1), 166–173 (2006).
   PubMed Web of Science ®Google Scholar
• Younes A, Fanale M, Pro B et al. A Phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. American Society of Clinical Oncology Annual Meeting Proceedings Part I25(Suppl. 18), 8000 (2007).
   Google Scholar
• Garcia-Manero G, Yang H, Sanchez-Gonzalez B et al. Final results of a Phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. American Society of Hematology Annual Meeting Abstracts106, 2801 (2007).
   Google Scholar
• Byrd JC, Marcucci G, Parthun MR et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood105(3), 959–967 (2005).
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Diliberto M et al. Multicenter Phase II trial of the histone deacetylase inhibitor depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). American Society of Hematology Annual Meeting Abstracts106(11), 2574 (2005).
   Google Scholar
• Gojo I, Jiemjit A, Trepel JB et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood109(7), 2781–2790 (2007).
   PubMed Web of Science ®Google Scholar
• Gimsing P, Wu F, Qian X et al. Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical studies and in a Phase I study in patients with advanced haematological tumors. American Society of Hematology Annual Meeting Abstracts106, 3337 (2005).
   Google Scholar
• Kaminskas E, Farrell A, Abraham S et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res.11, 3604–3608 (2005).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Holland JF, Weinberg RS et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia7(Suppl. 1), 21–29 (1993).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J. Clin. Oncol.20(10), 2429–2440 (2002).
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Herndon JE II, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol.20(10), 2441–2452 (2002).
   PubMed Web of Science ®Google Scholar
• Lyons RM, Cosgriff T, Modi S et al. Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. American Society of Clinical Oncology Annual Meeting Proceedings Part I25(Suppl. 18), 7083 (2007).
   Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer106(8), 1794–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood108(2), 419–425 (2006).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood109(1), 52–57 (2007).
   PubMed Web of Science ®Google Scholar
• Claus R, Wijermans P, Rüter B et al. Preferential Cytogenetic response to low dose decitabine in MDS with chromosome 7 abnormalities. European Haematology Association Annual Meeting (2007) (Abstract 0233).
   Google Scholar
• Scott SA, Lakshimikuttysamma A, Sheridan DP et al. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp. Hematol.35(2), 263–273 (2007).
   PubMed Web of Science ®Google Scholar
• Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev.20(1), 1–13 (2006).
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet.21(1), 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res.66(12), 6361–6369 (2006).
   PubMed Web of Science ®Google Scholar
• Maslak P, Chanel S, Camacho LH et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia20(2), 212–217 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase 1/2 study of the combination of 5-aza-2´-deoxycytidine with valproic acid in patients with leukemia. Blood108(10), 3271–3279 (2006).
   PubMed Web of Science ®Google Scholar
• Raffoux E, de Labarthe A, Gardin C et al. Sequential treatment with 5-azacytidine, valproic acid (VPA), and all-trans retinoic acid (ATRA) in patients with high-risk acute myeloid leukemia (AML). American Society of Hematology Annual Meeting Abstracts106, 2798 (2006).
   Google Scholar
• Soriano AO, Yang H, Tong W et al. Significant clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic (ATRA) acid in leukemia: results of a Phase I/II study. American Society of Hematology Annual Meeting Abstracts108, 160 (2006).
   Google Scholar
• Gore SD, Jiemjit A, Silverman LB et al. Combined methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. American Society of Hematology Annual Meeting Abstracts108, 517 (2006).
   Google Scholar
• Blum W, Klisovic RB, Hackanson B et al. Clinical, pharmacokinetic, and pharmacodynamic results of a Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol.25(25), 3884–3891 (2007).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med.341(27), 2061–2067 (1999).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer106(5), 1090–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood108(10), 3280–3288 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang AS, Klimek V et al. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). American Society of Clinical Oncology Annual Meeting Proceedings Part I25(Suppl. 18), 7062 (2007).
   Google Scholar
• Zhou DC, Kim SH, Ding W et al. Frequent mutations in the ligand-binding domain of PML–RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood99(4), 1356–1363 (2002).
   PubMed Web of Science ®Google Scholar
• Kitamura K, Hoshi S, Koike M et al. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol.108(4), 696–702 (2000).
   PubMed Web of Science ®Google Scholar
• Klisovic MI, Maghraby EA, Parthun MR et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia17(2), 350–358 (2003).
   PubMed Web of Science ®Google Scholar
• Tabe Y, Jin L, Contractor R et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ.14(8), 1443–1456 (2007).
   PubMed Web of Science ®Google Scholar
• Liu S, Klisovic RB, Vukosavljevic T et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J. Pharmacol. Exp. Ther.321(3), 953–960 (2007).
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D et al. The histone deacetylase inhibitor depsipeptide has differential activity in specific cytogenetic subsets of acute myeloid leukemia (AML). Blood104(11), A79 (2004).
   Google Scholar
• Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer106(1), 112–119 (2006).
   PubMed Web of Science ®Google Scholar
• Bug G, Ritter M, Wassmann B et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer104(12), 2717–2725 (2005).
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez B, Yang H, Bueso-Ramos C et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood108(4), 1174–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest. New Drugs25(1), 31–40 (2007).
   PubMed Web of Science ®Google Scholar
• Munster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol.25(15), 1979–1985 (2007).
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res.10(11), 3839–3852 (2004).
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T et al. Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood108(10), 3441–3449 (2006).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood109(12), 5143–5150 (2007).
   PubMed Web of Science ®Google Scholar
• Kawano T, Horiguchi-Yamada J, Iwase S et al. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr–Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res.24(5A), 2705–2712 (2004).
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Almenara J et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res.63(9), 2118–2126 (2003).
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr–Abl-positive human acute leukemia cells. Blood101(8), 3236–3239 (2003).
   PubMed Web of Science ®Google Scholar
• Fiskus W, Pranpat M, Bali P et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr–Abl-expressing human leukemia cells. Blood108(2), 645–652 (2006).
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Conrad D et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood102(10), 3765–3774 (2003).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Papavassiliou AG. 17-AAG: mechanisms of antitumour activity. Expert Opin. Investig. Drugs14(12), 1471–1474 (2005).
   PubMed Web of Science ®Google Scholar
• Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets6(3), 337–351 (2005).
   PubMed Web of Science ®Google Scholar
• Rahmani M, Yu C, Dai Y et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res.63(23), 8420–8427 (2003).
   PubMed Web of Science ®Google Scholar
• George P, Bali P, Annavarapu S et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood105(4), 1768–1776 (2005).
   PubMed Web of Science ®Google Scholar
• Huang HC, Liu YC, Liu SH et al. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci.70(15), 1763–1775 (2002).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood99(3), 1038–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9), 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang L, Liu Y et al. Histone deacetylase inhibitor promotes rituximab-induced apoptosis in non-hodgkin’s B-lymphoma cells by NF-κB-Mediated Bcl-2/Bcl-XL downregulation and c-Myc degradation. American Society of Hematology Annual Meeting Abstracts108, 2526 (2006).
   Google Scholar
• Dasmahapatra G, Almenara JA, Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol. Pharmacol.69(1), 288–298 (2006).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey RW, Zhan Z et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood103(12), 4636–4643 (2004).
   PubMed Web of Science ®Google Scholar
• Inoue S, MacFarlane M, Harper N et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ.11(Suppl. 2), S193–S206 (2004).
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Dai Y et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther.2(12), 1273–1284 (2003).
   PubMed Web of Science ®Google Scholar
• Musto P, Falcone A, Sanpaolo G et al. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica87(8), 884–886 (2002).
   PubMed Web of Science ®Google Scholar
• Westervelt P, Amirifeli S, Mehdi M et al. Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). American Society of Clinical Oncology Annual Meeting Proceedings Part I24(Suppl. 18), 6570 (2006).
   Google Scholar
• Kenealy MK, Seymour JF. Treatment of myelodysplastic syndromes with azacitidine and thalidomide. Leukemia Res.31(Suppl. 1), S7–S8 (2007).
   Google Scholar
• Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating agents. Semin. Hematol.42(3 Suppl. 2), S50–S59 (2005).
   PubMed Web of Science ®Google Scholar
• Balaian L, Ball ED. 5-azacytidine potentiates the anti-proliferative activity of anti-CD33 monoclonal antibodies (mAb) in acute myeloid leukemia in part through induction of Syk and SHP-1 expression. American Society of Hematology Annual Meeting Abstracts106, 2459 (2005).
   Google Scholar
• Boula A, Voulgarelis M, Giannouli S et al. Effect of cA2 anti-tumor necrosis factor-α antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin. Cancer Res.12(10), 3099–3108 (2006).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Cortes J et al. Results of decitabine (5-aza-2´deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer98(3), 522–528 (2003).
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian HM, Gharibyan V et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer109(5), 899–906 (2007).
   PubMed Web of Science ®Google Scholar
• Huang Y, Tan M, Gosink M, Wang KK, Sun Y. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res.62(10), 2913–2922 (2002).
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kovacs JJ, McLaurin A et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell115(6), 727–738 (2003).
   PubMed Web of Science ®Google Scholar
• Qian DZ, Kachhap SK, Collis SJ et al. Class II Histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res.66(17), 8814–8821 (2006).
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Bradner J et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem.280(29), 26729–26734 (2005).
   PubMed Web of Science ®Google Scholar
• Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs.16(5), 659–678 (2007).
   PubMed Web of Science ®Google Scholar